{"altmetric_id":6349537,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Actelion"],"first_seen_on":"2016-03-27T09:42:58+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1459063668,"links":["http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02719197","http:\/\/clinicaltrials.gov\/show\/NCT02719197"],"nct_id":"NCT02719197","pubdate":"2016-03-14T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7446125,"mean":6.4725723772484,"rank":1013748,"this_scored_higher_than_pct":85,"this_scored_higher_than":6366703,"rank_type":"exact","sample_size":7446125,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":275589,"mean":11.043466660377,"rank":55235,"this_scored_higher_than_pct":78,"this_scored_higher_than":216806,"rank_type":"exact","sample_size":275589,"percentile":78},"this_journal":{"total_number_of_other_articles":19440,"mean":9.9687869746386,"rank":3172,"this_scored_higher_than_pct":74,"this_scored_higher_than":14575,"rank_type":"exact","sample_size":19440,"percentile":74},"similar_age_this_journal_3m":{"total_number_of_other_articles":860,"mean":14.636675203725,"rank":111,"this_scored_higher_than_pct":76,"this_scored_higher_than":658,"rank_type":"exact","sample_size":860,"percentile":76}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["bioportfolio"],"posts_count":1}},"posts":{"news":[{"title":"First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders","url":"http:\/\/ct.moreover.com\/?a=25957818886&p=1pl&v=1&x=lUj3_P1v-vnU7COKbEEXmA","license":"public","citation_ids":[6349537,6349537],"posted_on":"2016-03-27T07:27:48+00:00","summary":"Summary The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy male adults Study Design Allocation: Randomized, Endpoint\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}]}}